Prognostic impact of metformin in solid cancer patients receiving immune checkpoint inhibitors: novel evidences from a multicenter retrospective study DOI Creative Commons
Jiaxin Wang, Jie Lin,

Huaijuan Guo

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: July 29, 2024

Objective: Metformin as a common antidiabetic drug, has recently found to exert its anti-cancer and immunomodulatory effect in numerous preclinical studies. This study aims clarify the prognostic impact of metformin use solid cancer patients receiving immune checkpoint inhibitors (ICIs). Methods: A retrospective cohort enrolling 516 who received ICI-based therapy between 2018 2023 at three hospitals was analyzed. The primary endpoints included overall survival (OS) progression-free (PFS). In addition, bioinformatics analysis based on TCGA GSE performed investigate significance target genes (MTGs) their correlation with infiltration non-small cell lung (NSCLC) patients. Results: entire cohort, total 76 before and/or during ICI therapy. global demonstrated that unrelated OS ( p = 0.064) PFS 0.059) ICI-treated patients, which confirmed subgroups esophagus, hepatobiliary or pancreatic (all > 0.05). However, significantly correlated better 0.012) 0.005) also identified an independent favorable factor for these five MTGs (RPS6KA5, RORA, SH3BP5, NUPR1, CD40LG) NSCLC all downregulated tissues compared normal tissues. expressions not only could effectively stratify but cells such CD4 + CD8 T cells. Conclusion: potential serve novel clinical biomarkers druggable targets immunotherapy. Considering limitations, actual needs be clarified by more trials.

Language: Английский

Prognostic impact of metformin in solid cancer patients receiving immune checkpoint inhibitors: novel evidences from a multicenter retrospective study DOI Creative Commons
Jiaxin Wang, Jie Lin,

Huaijuan Guo

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: July 29, 2024

Objective: Metformin as a common antidiabetic drug, has recently found to exert its anti-cancer and immunomodulatory effect in numerous preclinical studies. This study aims clarify the prognostic impact of metformin use solid cancer patients receiving immune checkpoint inhibitors (ICIs). Methods: A retrospective cohort enrolling 516 who received ICI-based therapy between 2018 2023 at three hospitals was analyzed. The primary endpoints included overall survival (OS) progression-free (PFS). In addition, bioinformatics analysis based on TCGA GSE performed investigate significance target genes (MTGs) their correlation with infiltration non-small cell lung (NSCLC) patients. Results: entire cohort, total 76 before and/or during ICI therapy. global demonstrated that unrelated OS ( p = 0.064) PFS 0.059) ICI-treated patients, which confirmed subgroups esophagus, hepatobiliary or pancreatic (all > 0.05). However, significantly correlated better 0.012) 0.005) also identified an independent favorable factor for these five MTGs (RPS6KA5, RORA, SH3BP5, NUPR1, CD40LG) NSCLC all downregulated tissues compared normal tissues. expressions not only could effectively stratify but cells such CD4 + CD8 T cells. Conclusion: potential serve novel clinical biomarkers druggable targets immunotherapy. Considering limitations, actual needs be clarified by more trials.

Language: Английский

Citations

3